SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Bob Stocks, runncoach, PatrickBateman, kld2
Search This Board: 
Last Post: 4/25/2017 6:00:46 AM - Followers: 66 - Board type: Free - Posts Today: 5

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017

COMPANY PRESENTATION

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
 
 
 
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NTRP News: Notice of Effectiveness (effect) 04/24/2017 06:01:54 AM
NTRP News: Current Report Filing (8-k) 04/14/2017 05:23:52 PM
NTRP News: Securities Registration Statement (simplified Form) (s-3/a) 04/14/2017 05:21:37 PM
NTRP News: Notice of Effectiveness (effect) 04/10/2017 06:02:12 AM
NTRP News: Notice of Effectiveness (effect) 04/10/2017 06:02:12 AM
PostSubject
#3579  Sticky Note OK folks. While we realize that an occasional IH Admin [Edward] 04/17/17 09:53:57 PM
#1870  Sticky Note NTRP has updated their Company presentation on their website: SF Wolf 03/14/17 08:33:06 AM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#679  Sticky Note February 13 conference...includes results from compassionate use patients runncoach 02/13/17 03:30:18 PM
#3955   every other scientist has unveiled an empty cage, kld2 04/25/17 06:00:46 AM
#3954   Ray, sorry to hear about your dad as kld2 04/25/17 05:56:06 AM
#3953   "and most of all, this trial are ripe runncoach 04/25/17 03:03:50 AM
#3952   exactly Donsker, exactly 1hb 04/25/17 01:33:53 AM
#3951   xX - nice post, really nice post, very 1hb 04/25/17 01:03:03 AM
#3950   "The sell on the news theory has no blu_1 04/24/17 09:58:40 PM
#3949   My take on this is: (1). SP donsker 04/24/17 08:30:06 PM
#3948   There's absolutely no reason to worry about the xIdXd 04/24/17 08:17:25 PM
#3947   Runncoach and Ray - first look at my 1hb 04/24/17 06:56:47 PM
#3946   Ray, if bad news had leaked we would runncoach 04/24/17 05:10:02 PM
#3945   Ray, Chupacabra Gigante 04/24/17 05:09:14 PM
#3944   Here's my take and after I write it kc44 04/24/17 05:06:01 PM
#3943   Nice note today from Investor Relations at Neurotrope... Ray Winston 04/24/17 04:44:45 PM
#3942   Ok Cad, one key is price you own 1hb 04/24/17 03:43:50 PM
#3941   Crash doesn't describe a pull back from a donsker 04/24/17 03:34:01 PM
#3940   Doubt Maple tree 04/24/17 03:33:16 PM
#3939   Great, we'll get an even better price. donsker 04/24/17 03:31:30 PM
#3938   Wrong. Higher volume and a 8.11% drop already blu_1 04/24/17 03:09:00 PM
#3937   do elighten cadfxguy 04/24/17 03:02:20 PM
#3936   With bios up today this should fall heavy tomorrow Bearly Bullish 04/24/17 02:55:19 PM
#3935   Cad, let me help you out...it would be 1hb 04/24/17 02:48:16 PM
#3934   If you do not own any options Whatsupp 04/24/17 02:39:56 PM
#3933  Restored "Rather than obsess about charts and the stock Whatsupp 04/24/17 02:36:11 PM
#3932   Buy to open, or close? cadfxguy 04/24/17 02:29:37 PM
#3931  Restored Exactly donsker, once the Top Line results are SF Wolf 04/24/17 02:20:25 PM
#3930   Thanks for the explanation my friend. cadfxguy 04/24/17 02:09:37 PM
#3929   And it's bounced 50 Cent since this post runncoach 04/24/17 01:48:59 PM
#3927   At least their not selling shares into the Bearly Bullish 04/24/17 01:35:24 PM
#3926   NTRP Chart As expected we are seeing volume bUrRpPPP! 04/24/17 01:35:10 PM
#3925   Means very little as data results are the donsker 04/24/17 01:31:55 PM
#3924   Nothing to stop the hedge funds involved from XenaLives 04/24/17 01:31:01 PM
#3923   360 minute chart, not pretty... XenaLives 04/24/17 01:29:25 PM
#3922   I agree, this is classic accumulation tactics. Picked donsker 04/24/17 01:19:42 PM
#3920   There is two plays you can make. Whatsupp 04/24/17 01:08:19 PM
#3918   i'm long, but as a newer investor I've cadfxguy 04/24/17 12:56:15 PM
#3917   All this increased volume around 17 is giving xIdXd 04/24/17 12:54:22 PM
#3916   FACT - NO INSIDERS CAN SELL NOW as 1hb 04/24/17 12:52:46 PM
#3912   NTRP now subject to FINRA Rule 6190 SF Wolf 04/24/17 12:16:33 PM
#3911   Squeezing the cheeks so hard right now... hnnngg. resident1 04/24/17 12:01:35 PM
#3910   Today is a great lesson on why you xIdXd 04/24/17 11:57:41 AM
#3908   Higher volume/action most likely due to Options traders bUrRpPPP! 04/24/17 11:41:26 AM
#3906   This shelf filing will be crossed with institutions, Chupacabra Gigante 04/24/17 11:39:53 AM
#3905   Yes looks to me like the big chunks Whatsupp 04/24/17 11:39:04 AM
#3904   Maybe part of the release will be a Whatsupp 04/24/17 11:37:57 AM
#3903   Anyone else watching L2? Been seeing some of Selett 04/24/17 11:37:28 AM
#3902   No crystal ball but logical guessing. When they filed Amatuer17 04/24/17 11:36:38 AM
#3901   Zero reason to believe that runncoach 04/24/17 11:35:06 AM
#3900   You make this statement as if you know kc44 04/24/17 11:31:02 AM
#3899   Just bc it went effective today doesn't mean Selett 04/24/17 11:28:24 AM
#3898   The shelf filing became effective today - so Amatuer17 04/24/17 11:27:09 AM
PostSubject